Skip to main content

Advertisement

Table 3 Efficacy of third-generation EGFR TKIs in EGFR T790M-positive NSCLC patients

From: Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

Drug Trial Patients (N) Dose ORR T790M PFS (mo.)
Osimertinib AURA phase I [92] Total: 253 T790M(+): 138 20-240 mg QD T790M(+): 61% T790M(−): 21% T790M(+): 9.6 T790M(−): 2.8
AURA phase I T790M(+) 63 80 mg QD 71% 9.7
AURA phase II 210 80 mg QD 70% 9.9
AURA phase II extension [132] 411 80 mg QD 62% 12.3
AURA phase III [84] 416 -Osimertinib arm: 279 -Chemotherapy arm: 140   71% 31% Odds ratio:5.39 (95% CI: 3.47–8.48) 10.1 4.4 HR: 0.30 (95% CI: 0.23–0.41)
Rociletinib TIGER-X phase I/II [98] Total: 69 T790M(+): 51 500, 625 or 750 mg bid 45% T790M(+): 9.6 T790M(−): 2.8
Olmutinib HM-EMSI-101 phase I/II T790M(+) [133] 76 800 mg QD 62% 6.9
ASP8273 NCT02113813 phase I/II [134] Total: 63 T790M(+): 58 300 mg QD 29% 6.8
Nazartinib NCT02108964 phase I/II [105] 152 75-350 mg QD 46.9% 9.7
Avitinib (AC0010) NCT02330367 phase I/II [106] 136 50-350 mg QD 44%